Wake Up to the Possibilities of Reaching Your A1C Goal
RYBELSUS® is proven to lower blood sugar and A1C
In a 6-month study of people with an average starting A1C of 8%, the majority of people taking RYBELSUS® reached an A1C of less than 7%a:
• Nearly 7 out of 10 people on 7 mg of RYBELSUS®
• Nearly 8 out of 10 people on 14 mg of RYBELSUS®
• About 3 out of 10 people on a sugar pill
If eligible, you may pay as little as $10 for a 30-day prescriptionc
What is Rybelsus®?
Rybelsus® (semaglutide) tablets 7 mg or 14 mg is a prescription medicine for adults with type 2 diabetes that along with diet and exercise may improve blood sugar (glucose).
• Rybelsus® is not recommended as the first choice of medicine for treating diabetes
• It is not known if Rybelsus® can be used in people who have had pancreatitis
• Rybelsus® is not for use in people with type 1 diabetes and people with diabetic ketoacidosis
• It is not known if Rybelsus® is safe and effective for use in children under 18 years of age
Important Safety Information
What is the most important information I should know about Rybelsus®?
Rybelsus® may cause serious side effects, including:
• Possible thyroid tumors, including cancer.
Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Rybelsus® and medicines that work like Rybelsus® caused thyroid tumors, including thyroid cancer. It is not known if Rybelsus® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people
Do not use Rybelsus® if:
• you or any of your family have ever had MTC, or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• you are allergic to semaglutide or any of the ingredients in Rybelsus®
RYBELSUS® may help you lose some weight
While not for weight loss, in the same 6-month study, people with an average starting weight of 195 pounds lost up to 8 poundsa:
• 5 pounds on 7 mg of RYBELSUS®
• 8 pounds on 14 mg of RYBELSUS®
• 3 pounds on a sugar pill
While many people in medical studies lost weight, some did gain weight.
Before using Rybelsus®, tell your healthcare provider if you have any other medical conditions, including if you:
• have or have had problems with your pancreas or kidneys
• have a history of vision problems related to your diabetes
• are pregnant or plan to become pregnant. It is not known if Rybelsus® will harm your unborn baby. You should stop using Rybelsus® 2 months before you plan to become pregnant. Talk to your healthcare provider about the best way to control your blood sugar if you plan to become pregnant or while you are pregnant
• are breastfeeding or plan to breastfeed. Breastfeeding is not recommended during treatment with Rybelsus®
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Rybelsus® may affect the way some medicines work and some medicines may affect the way Rybelsus® works.
What are the possible side effects of Rybelsus®? Rybelsus® may cause serious side effects, including:
• inflammation of your pancreas (pancreatitis).
Stop using Rybelsus® and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back
• changes in vision. Tell your healthcare provider if you have changes in vision during treatment with Rybelsus®
• low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Rybelsus® with another medicine that can
RYBELSUS® does not increase the risk of major cardiovascular (CV) events such as heart attack, stroke, or deathb
ain a 6-month study looking at A1C with 703 adults with T2D comparing 7 mg RYBELSUS® and 14 mg RYBELSUS® with a sugar pill when both were added to diet and exercise. bin a cardiovascular safety study, 3183 adults with T2D and a high risk of CV events were treated with either 14 mg RYBELSUS® or a sugar pill in addition to their usual diabetes and CV medications.
Textd RESULTS to 44535 to learn more about RYBELSUS® cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include: dizziness or lightheadedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, and feeling jittery
• kidney problems (kidney failure). In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration
• serious allergic reactions. Stop using Rybelsus® and get medical help right away, if you have any symptoms of a serious allergic reaction including itching, rash, or difficulty breathing
The most common side effects of Rybelsus® may include nausea, stomach (abdominal) pain, diarrhea, decreased appetite, vomiting, and constipation. Nausea, vomiting, and diarrhea are most common when you first start Rybelsus®.
Please see Brief Summary of Prescribing Information on adjacent page.
ccommercially insured patients only. Offer valid for up to six 30-day fills. Eligibility and other restrictions apply. dmessage and data rates may apply. Check with your mobile service provider. Message frequency will be based on your selections. Text HELP to 44535 for help. Text STOP to 44535 to quit. See Terms and Conditions of Use at RYBELSUS.COM. See cost and savings info at RYBELSUS.COM, and ask your healthcare provider about RYBELSUS® today.
Rx Only
This information is not comprehensive.
• Talk to your healthcare provider or pharmacist
• Visit www.novo-pi.com/rybelsus.pdf to obtain the Fda-approved product labeling
• Call 1-833-GLP-PILL
Read this Medication Guide before you start using RYBELSUS® and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.
What is the most important information I should know about RYBELSUS®?
RYBELSUS® may cause serious side effects, including:
• Possible thyroid tumors, including cancer. Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, RYBELSUS® and medicines that work like RYBELSUS® caused thyroid tumors, including thyroid cancer. It is not known if RYBELSUS® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people.
• Do not use RYBELSUS® if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC), or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
What is RYBELSUS®?
RYBELSUS® is a prescription medicine used along with diet and exercise to improve blood sugar (glucose) in adults with type 2 diabetes.
• RYBELSUS® is not recommended as the first choice of medicine for treating diabetes.
• It is not known if RYBELSUS® can be used in people who have had pancreatitis.
• RYBELSUS® is not for use in patients with type 1 diabetes and people with
diabetic ketoacidosis.
It is not known if RYBELSUS® is safe and effective for use in children under 18 years
of age.
Do not use RYBELSUS® if:
• you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• you are allergic to semaglutide or any of the ingredients in RYBELSUS®.
Before using RYBELSUS®, tell your healthcare provider if you have any other medical conditions, including if you:
• have or have had problems with your pancreas or kidneys.
• have a history of vision problems related to your diabetes.
• are pregnant or plan to become pregnant. It is not known if RYBELSUS® will harm your unborn baby. You should stop using RYBELSUS® 2 months before you plan to become pregnant. Talk to your healthcare provider about the best way to control your blood sugar if you plan to become pregnant or while you are pregnant.
• are breastfeeding or plan to breastfeed. Breastfeeding is not recommended during treatment with RYBELSUS®.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RYBELSUS® may affect the way some medicines work and some medicines may affect the way RYBELSUS® works.
Before using RYBELSUS®, talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking other medicines to treat diabetes, including insulin or sulfonylureas.
Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.
Manufactured by: Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark RYBELSUS® is a registered trademark of Novo Nordisk A/S.
© 2020 Novo Nordisk US20RYB00078 2/2020
How should I take RYBELSUS®?
• Take RYBELSUS® exactly as your healthcare provider tells you to.
• Take RYBELSUS® by mouth on an empty stomach when you first wake up.
• Take RYBELSUS® with a sip of water (no more than 4 ounces).
• Do not split, crush or chew. Swallow RYBELSUS® whole.
• After 30 minutes, you can eat, drink, or take other oral medications.
RYBELSUS® works best if you eat 30 to 60 minutes after taking RYBELSUS®. • If you miss a dose of RYBELSUS®, skip the missed dose and go back to your
regular schedule.
• Talk to your healthcare provider about how to prevent, recognize and manage low blood sugar (hypoglycemia), high blood sugar (hyperglycemia), and problems
you have because of your diabetes.
What are the possible side effects of RYBELSUS®?
RYBELSUS® may cause serious side effects, including:
• See “What is the most important information I should know about RYBELSUS®?” • inflammation of your pancreas (pancreatitis). Stop using RYBELSUS® and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting.
You may feel the pain from your abdomen to your back.
• changes in vision. Tell your healthcare provider if you have changes in vision during treatment with RYBELSUS®.
• low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use RYBELSUS® with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include: dizziness or light-headedness blurred vision anxiety, irritability, or mood changes sweating slurred speech hunger confusion or drowsiness shakiness weakness headache fast heartbeat feeling jittery
• kidney problems (kidney failure). In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration) which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration. • serious allergic reactions. Stop using RYBELSUS® and get medical help right away, if you have any symptoms of a serious allergic reaction including itching, rash, or difficulty breathing.
The most common side effects of RYBELSUS® may include nausea, stomach (abdominal) pain, diarrhea, decreased appetite, vomiting and constipation. Nausea, vomiting and diarrhea are most common when you first start RYBELSUS®. Talk to your healthcare provider about any side effect that bothers you or does not go away. These are not all the possible side effects of RYBELSUS®.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store RYBELSUS®?
• Store RYBELSUS® at room temperature between 68°F and 77°F (20°C to 25°C).
• Store in a dry place away from moisture.
• Store tablet in the original pack.
• Keep the tablet in the pack until you are ready to take it.
• Keep RYBELSUS® and all medicines out of the reach of children.
Revised: 01/2020